Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Second Date For Merck: Retrial Set For Feb. 6

This article was originally published in The Pink Sheet Daily

Executive Summary

A retrial of the first federal Vioxx product liability case is scheduled to begin on Feb. 6, the firm announced

You may also be interested in...



Win, Lose & Draw: Third Merck Vioxx Trial Ends In Mistrial

A Houston jury was unable to reach a verdict in the first federal product liability trial over the COX-2 inhibitor.

Vioxx Cardiovascular Outcomes Withheld From VIGOR Article, NEJM Says

Additional cardiovascular events from the VIGOR study were known by study authors but not included in the manuscript submission to the New England Journal of Medicine, the journal says.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Topics

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel